A Phase I Open-Label Study to Assess the Safety and Tolerability of KU-0059436 in Combination With Carboplatin KU-0059436 in Combination With a Paclitaxel/Carboplatin T/C Doublet and KU-0059436 in Combination With Paclitaxel in the Treatment of Patients With Advanced Solid Tumours
Latest Information Update: 14 May 2024
At a glance
- Drugs Olaparib (Primary) ; Carboplatin; Paclitaxel
- Indications Advanced breast cancer; Ovarian cancer; Solid tumours
- Focus Adverse reactions
- Sponsors AstraZeneca
- 09 May 2024 Status changed from active, no longer recruiting to completed.
- 15 Jan 2024 Planned End Date changed from 29 Dec 2023 to 31 Dec 2024.
- 19 Dec 2022 Planned End Date changed from 30 Dec 2022 to 29 Dec 2023.